Status: Not yet recruiting
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.Updated: Jun 15, 2026Locations: 1
Eligibility criteria
BMI 19.0-28.0 kg/m², with male subjects weighing ≥50.0 kg and female subjects we... [+1]
A history of past or current conditions involving the nervous system, cardiovasc... [+2]